Ishibashi Foundation for the Promotion of Science;Takeda Science Foundation;Shinnihon Foundation of Advanced Medical Treatment Research;the Kurume University Branding Project;the Yasuda Medical Foundation;the JSPS KAKENHI grant。
Background:Antiangiogenic tyrosine kinase inhibitors(TKIs)provide one of the few therapeutic options for effective treatment of hepatocellular carcinoma(HCC).However,patients with HCC often develop resistance toward a...